EFFECT OF EZETIMIBE PLUS LOW-DOSE ATORVASTATIN VERSUS DOUBLE-DOSE ATORVASTATIN ON INSULIN RESISTANCE AND LIPID METABOLISM IN CORONARY ARTERY DISEASE PATIENTS WITH OR WITHOUT METABOLIC SYNDROME